Skip to content

ASCELIA

AN ONCOLOGY-DEDICATED DRUG DEVELOPMENT COMPANY

 
  • EnEn
  • SvSv
  • About us
    • Management
    • Board of Directors
  • Therapeutic areas
    • Liver metastases
    • Gastric Cancer
  • Pipeline
    • Orviglance® (Mangoral)
    • Oncoral
  • Partnering
  • IR & Media
    • Press releases
    • Financial Reports
    • Presentations & articles
    • Share
    • Shareholders
    • Insiders
    • Equity research
    • Financial calendar
    • Events
    • IR Contact
    • Prospectuses
    • CMD 2020
    • Subscribe to press releases
  • Governance
    • General Meeting
    • Articles of Association
    • Nomination Committee
    • Board of Directors
    • Audit Committee
    • Remuneration Committee
    • Commercialization Committee
    • Remuneration
    • Auditors
    • Internal control
  • Career
    • Open positions
    • Our values
    • Meet us
  • Contact
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
Subscribe to press releases
All All press releasesRegulatory press releasesFinancial reports
2023-01-27 | 71 patients have completed the SPARKLE study
PDF
Report
Financial Data
Presentation
Webcast
2022-12-29 | 65 patients have completed the SPARKLE study
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2022-12-06 | New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2022-12-02 | Nomination Committee appointed for AGM 2023 in Ascelia Pharma AB
PDF
Report
Financial Data
Presentation
Webcast
2022-11-30 | ASCELIA PHARMA PRESENTS RESULTS OF ORVIGLANCE FOOD EFFECT STUDY AT RSNA 2022 SHOWING STRONG LIVER ENHANCEMENT BOTH WITH LIGHT MEAL AND IN FASTING CONDITION
PDF
Report
Financial Data
Presentation
Webcast
2022-10-05 | Ascelia Pharma expands its leadership team
PDF
Report
Financial Data
Presentation
Webcast
2022-09-28 | Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study
PDF
Report
Financial Data
Presentation
Webcast
2022-08-11 | Ascelia Pharma to present Orviglance Food Effect Study at 2022 RSNA Annual Meeting
PDF
Report
Financial Data
Presentation
Webcast
2022-06-20 | Ascelia Pharma appoints Déspina Georgiadou Hedin as new CFO
PDF
Report
Financial Data
Presentation
Webcast
2022-06-01 | Results from Orviglance comparison study to gadolinium presented at ESGAR 2022 conference
PDF
PDF
Report
Financial Data
Presentation
Webcast
2022-05-31 | Ascelia Pharma second US patent for Oncoral (oral irinotecan) strengthens coverage
PDF
Report
Financial Data
Presentation
Webcast
2022-05-10 | Ascelia Pharma’s Food Effect Study shows that Orviglance image enhancement of the liver is not reduced by light meal
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2022-05-05 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 5 May 2022
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2022-04-05 | NOTICE OF ANNUAL GENERAL MEETING IN ASCELIA PHARMA AB
PDF
Report
Financial Data
Presentation
Webcast
2022-04-01 | CFO Kristian Borbos to leave Ascelia Pharma
PDF
Report
Financial Data
Presentation
Webcast
2022-03-22 | New independent market research says 84% US healthcare professionals likely to use Orviglance imaging agent in target population
PDF
PDF
Report
Financial Data
Presentation
Webcast
2022-03-11 | Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study
PDF
Report
Financial Data
Presentation
Webcast
Regulatory
2022-03-07 | Ascelia Pharma suspends clinical activities in Russia
PDF
Report
Financial Data
Presentation
Webcast

Posts navigation

Older posts
Learn more

About us

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. […]
Learn more

Meet us

Ascelia’s employees are passionate and driven to develop products that will help people with rare cancer conditions live longer and healthier lives.
Learn more

Our values

Our values inspire our ambitions, decision making and collaboration to help us reach our highest potential. INTEGRITY We build powerful relationship with mutual respect and adhere to the high ethical […]
  1. Start

About us

  • Start
  • About us
  • Career
  • Contact
  • Privacy policy
  • About cookies
  • Cookie settings

Pipeline

  • Oncoral
  • Orviglance®

IR & Media

  • Subscribe to press releases
  • Press releases & News
  • Financial Reports

Contact us

Ascelia Pharma AB
Hyllie Boulevard 34
215 32 Malmö
Sweden
Phone: +46 735 17 91 18

info@ascelia.com

Follow us

 

Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (former working name Mangoral) and Oncoral – in clinical development.

Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE).

© Copyright 2021 - Ascelia Pharma AB | We use cookies to improve our services | Disclaimer Market data could be delayed. Delivered by Modular Finance.

Video
Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all